ChemicalBook > CAS DataBase List > Tarlatamab

Tarlatamab

Product Name
Tarlatamab
CAS No.
2307488-83-9
Chemical Name
Tarlatamab
Synonyms
Tarlatamab;Research Grade Tarlatamab;Tarlatamab (anti-DLL3&CD3);Research Grade Tarlatamab (DHK06402)
CBNumber
CB510617037
Formula Weight
0
MOL File
Mol file
More
Less

Tarlatamab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Tarlatamab Chemical Properties,Usage,Production

Uses

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research[1].

in vivo

Tarlatamab (AMG-757; 3 mg/kg; IP; once weekly for 3 weeks) drives tumor regression in mouse models of SCLC[1].
Tarlatamab (IP; 12 μg/kg; single dose) has a mean half-life of 234 hours (9.8 days), a mean clearance of 0.487 mL/hour/kg and a steady-state volume of distribution of 146 mL/kg in nonhuman primates (NHPs)[1].

Animal Model:Female NOD.Cg-PrkdcscidIl2rgtm1Sug/JicTac (NOG) mice with patient-derived SCLC tumor fragments (LXFS 1129 and LXFS 538)[1]
Dosage:3 mg/kg
Administration:IP; once weekly for 3 weeks
Result:Led to 83% tumor regression and an overall significant reduction in tumor volume compared with that in mice which received a control HLE BiTE molecule in the LXFS 1129 model.
Induced 98% tumor regression in the LXFS 538 model.

References

[1] Michael J Giffin, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. DOI:10.1158/1078-0432.CCR-20-2845

Tarlatamab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Tarlatamab Suppliers

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
89689
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
7999
Advantage
62
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24960
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9866
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
7062
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
49665
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509 17721492509
Email
460170712@qq.com
Country
China
ProdList
4894
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
18229892877 13823398779
Email
3062105966@qq.com
Country
China
ProdList
5350
Advantage
58
SHAANXI?DIDEU?MEDICHEM CO.LTD
Tel
17691182729 17392216275
Email
1102@dideu.com
Country
China
ProdList
9996
Advantage
58

2307488-83-9, TarlatamabRelated Search:


  • Tarlatamab
  • Research Grade Tarlatamab (DHK06402)
  • Research Grade Tarlatamab
  • Tarlatamab (anti-DLL3&CD3)
  • 2307488-83-9